Loading...

Codexis, Inc.

0I0X.L•LSE
Healthcare
Biotechnology
£3.04
£0.29(10.55%)

Codexis, Inc. (0I0X.L) Stock Overview

Explore Codexis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.4/100

Key Financials

Market Cap254.2M
P/E Ratio-3.42
EPS (TTM)$-0.32
ROE-1.18%
Fundamental Analysis

AI Price Forecasts

1 Week$2.31
1 Month$1.90
3 Months$0.52
1 Year Target$5.80

0I0X.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Codexis, Inc. (0I0X.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 70.86, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $5.80.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.42 and a market capitalization of 254.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

70.86RSI (14)
0.13MACD
23.01ADX
Revenue Growth
-15.39%
↓ 15.39%
Profit Growth
£-0.90
↑ 14.38%
EPS Growth
£-0.90
↑ 20.54%
Operating Margin
-134.40%
↑ 14.03%
ROE
-118.47%
↑ 14.38%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0I0X.LAnalyst Recommendations details for 0I0X.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CEO

Stephen George Dilly MBBS,

Employees

188

Headquarters

200 Penobscot Drive, Redwood City, CA

Founded

2018

Frequently Asked Questions

;